Form 10-Q · Quarterly report
IQVIA 10-Q, filed Jul 28, 2026
- Filed
- CIK
- 0001478242
- Accession no.
- 0001628280-26-050211
Summary
IQVIA reported second-quarter 2026 revenues of $4.368 billion, up 8.7% from a year earlier, and first-half revenues of $8.519 billion, up 8.6%. Effective January 1, 2026, the company reorganized into two reportable segments—Commercial Solutions and Research & Development Solutions—and incurred higher restructuring costs as it streamlined operations.
Key points
- IQVIA reported second-quarter 2026 revenues of $4.368 billion, up 8.7% from the same period in 2025.
- First-half 2026 revenues were $8.519 billion, up 8.6% year over year.
- Effective January 1, 2026, IQVIA moved Contract Sales & Medical Solutions into a renamed Commercial Solutions segment and moved some Real-World offerings into Research & Development Solutions, leaving two reportable segments.
- Restructuring costs were $63 million in the second quarter and $114 million in the first half of 2026, tied to streamlining operations and integrating acquisitions.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.